A review of the molecular mechanisms of chemically induced neoplasia in rat and mouse models in national toxicology program bioassays and their relevance to human cancer

Toxicologic Pathology

Volumn 37, Issue 7, 2009, Pages 835-848

  Hoenerhoff, Mark J ^a   Hong, Hue Hua ^a   Ton, Tai Vu ^a   Lahousse, Stephanie A ^a   Sills, Robert C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Animal models; Cancer; Carcinogenesis; Genotoxins non genotoxins; Risk identification.; Rodent pathology; Toxicologic pathology

Indexed keywords

APC PROTEIN; ASBESTOS; BETA CATENIN; CARCINOGEN; CHEMICAL COMPOUND; CHLOROPRENE; CUMENE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DIETHANOLAMINE; ETHYLENE OXIDE; METHOXSALEN; METHYLEUGENOL; MITOGEN ACTIVATED PROTEIN KINASE P38; OXAZEPAM; PROTEIN BCL 2; PROTEIN FOS; PROTEIN P16; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SOMATOMEDIN; VASCULOTROPIN; WT1 PROTEIN; ZIDOVUDINE;

ANIMAL MODEL; BIOASSAY; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CARCINOGENICITY; CELL CYCLE REGULATION; CELL INTERACTION; CHEMICAL CARCINOGENESIS; CHEMICALLY INDUCED DISORDER; COLON CANCER; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE MUTATION; GENETICS; GENOTOXICITY; HEALTH HAZARD; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MESOTHELIOMA; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUVA; REVIEW; RISK ASSESSMENT; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR GENE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET A RADIATION;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; CARCINOGENS, ENVIRONMENTAL; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; GENES, NEOPLASM; HUMANS; MICE; NATIONAL HEALTH PROGRAMS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; RISK ASSESSMENT;

ANIMALIA; RATTUS; RODENTIA;

EID: 74849140984     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309351726     Document Type: Review

References (153)

1. Anna, C.H., Iida, M., Sills, R.C., and Devereux, T.R. (2003). Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice. Toxicol Appl Pharmacol 190, 135-145.
2. Anna, C.H., Sills, R.C., Foley, J.F., Stockton, P.S., Ton, T.V., and Devereux, T.R. (2000). Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. Cancer Res 60, 2864-2868.
3. Bachoo, R.M., Maher, E.A., Ligon, K.L., Sharpless, N.E., Chan, S.S., You, M.J., Tang, Y., DeFrances, J., Stover, E., Weissleder, R., Rowitch, D.H., Louis, D.N., and DePinho, R.A. (2002). Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269-277.
4. Balmain, A., and Pragnell, I.B. (1983). Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 303, 72-74.
5. Bhana, N., Ormrod, D., Perry, C.M., and Figgitt, D.P. (2002). Zidovudine: A review of its use in the management of vertically-acquired pediatric HIV infection. Paediatr Drugs 4, 515-553.
6. Bienz, M., and Clevers, H. (2000). Linking colorectal cancer to Wnt signaling. Cell 103, 311-320.
7. Bos, J.L., Fearon, E.R., Hamilton, S.R., Verlaan- de Vries, M., van Boom, J.H., van der Eb, A.J., and Vogelstein, B. (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-297.
8. Brown, K., Buchmann, A., and Balmain, A. (1990). Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci U S A 87, 538-542.
9. Carbone, M., and Bedrossian, C.W. (2006). The pathogenesis of mesothelioma. Semin Diagn Pathol 23, 56-60.
10. Cherian, M.G., Jayasurya, A., and Bay, B.H. (2003). Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533, 201-209.
11. Christensen, B.C., Godleski, J.J., Marsit, C.J., Houseman, E.A., Lopez-Fagundo, C.Y., Longacker, J.L., Bueno, R., Sugarbaker, D.J., Nelson, H.H., and Kelsey, K.T. (2008). Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 29, 1555-1559.
12. Coleman, W.B. (2003). Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3, 573-588.
13. Connor, E.M., Sperling, R.S., Gelber, R., Kiselev, P., Scott, G., O′Sullivan, M.J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R.L., et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331, 1173-1180.
14. Datta, S., Hoenerhoff, M.J., Bommi, P., Sainger, R., Guo, W.-J., Dimri, M., Band, H., Band, V., Green, J.E., and Dimri, G.P. (2007). Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Research 67, 10286-10295.
15. Davies, R.J., Miller, R., and Coleman, N. (2005). Colorectal cancer screening: Prospects for molecular stool analysis. Nat Rev Cancer 5, 199-209.
16. de Gruijl, F.R. (2000). Photocarcinogenesis: UVA vs UVB. Methods Enzymol 319, 359-366.
17. de Gruijl, F.R., van Kranen, H.J., and Mullenders, L.H. (2001). UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B 63, 19-27.
18. Devereux, T.R., Anna, C.H., Foley, J.F., White, C.M., Sills, R.C., and Barrett, J.C. (1999). Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene 18, 4726-4733.
19. Diwan, B.A., Riggs, C.W., Logsdon, D., Haines, D.C., Olivero, O.A., Rice, J.M., Yuspa, S.H., Poirier, M.C., and Anderson, L.M. (1999). Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′- deoxythymidine in mice. Toxicol Appl Pharmacol 161, 82-99.
20. Donnelly, P.J., Devereux, T.R., Foley, J.F., Maronpot, R.R., Anderson, M.W., and Massey, T.E. (1996). Activation of K-ras in aflatoxin B1-induced lung tumors from AC3F1 (A/J x C3H/HeJ) mice. Carcinogenesis 17, 1735-1740.
21. Dunnick, J.K., Burka, L.T., Mahler, J., and Sills, R. (2003). Carcinogenic potential of o-nitrotoluene and p-nitrotoluene. Toxicology 183, 221-234.
22. Dunnick, J.K., Forbes, P.D., Eustis, S.L., Hardisty, J.F., and Goodman, D.G. (1991). Tumors of the skin in the HRA/Skh mouse after treatment with 8-methoxypsoralen and UVA radiation. Fundam Appl Toxicol 16, 92-102.
23. Fausto, N. (1999). Mouse liver tumorigenesis: Models, mechanisms, and relevance to human disease. Semin Liver Dis 19, 243-252.
24. Fearon, E.R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
25. Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., Whitsett, J.A., Koretsky, A., and Varmus, H.E. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15, 3249-3262.
26. Fodde, R., Smits, R., and Clevers, H. (2001). APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1, 55-67.
27. Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M.E., Janzer, R.C., Merlo, A., and Van Meir, E.G. (2000). p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19, 3816-3822.
28. Gasparro, F.P., Felli, A., and Schmitt, I.M. (1997). Psoralen photobiology: The relationship between DNA damage, chromatin structure, transcription, and immunogenic effects. Recent Results Cancer Res 143, 101-127.
29. Gerbes, A.L., and Caselmann, W.H. (1993). Point mutations of the P53 gene, human hepatocellular carcinoma and aflatoxins. J Hepatol 19, 312-315.
30. Goldstein, N.S., Long, A., Kuan, S.F., and Hart, J. (2000). Colon signet ring cell adenocarcinoma: Immunohistochemical characterization and comparison with gastric and typical colon adenocarcinomas. Appl Immunohistochem Mol Morphol 8, 183-188.
31. Hainaut, P., Hernandez, T., Robinson, A., Rodriguez-Tome, P., Flores, T., Hollstein, M., Harris, C.C., and Montesano, R. (1998). IARC Database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 26, 205-213.
32. Halevy, O., Michalovitz, D., and Oren, M. (1990). Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250, 113-116.
33. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
34. Haseman, J.K., Arnold, J., and Eustis, S.L. (1990). Tumor Incidences in Fischer 344 Rats: NTP Historical Data. Academic Press, San Diego, CA.
35. Hayashi, S.M., Ton, T.V., Hong, H.H., Irwin, R.D., Haseman, J.K., Devereux, T.R., and Sills, R.C. (2003). Genetic alterations in the Catnb gene but not the H-ras gene in hepatocellular neoplasms and hepatoblastomas of B6C3F(1) mice following exposure to diethanolamine for 2 years. Chem Biol Interact 146, 251-261.
36. Hecht, S.S. (1999). Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91, 1194-1210.
37. Herbst, R.S., Heymach, J.V., and Lippman, S.M. (2008). Lung cancer. N Engl J Med 359, 1367-1380.
38. Himmelstein, M.W., Acquavella, J.F., Recio, L., Medinsky, M.A., and Bond, J.A. (1997). Toxicology and epidemiology of 1,3-butadiene. Crit Rev Toxicol 27, 1-108.
39. Holland, E.C. (2001). Gliomagenesis: Genetic alterations and mouse models. Nat Rev Genet 2, 120-129.
40. Holsapple, M.P., Pitot, H.C., Cohen, S.M., Boobis, A.R., Klaunig, J.E., Pastoor, T., Dellarco, V.L., and Dragan, Y.P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 89, 51-56.
41. Hong, H.H., Dunnick, J., Herbert, R., Devereux, T.R., Kim, Y., and Sills, R.C. (2007). Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. Environ Mol Mutagen 48, 299-306.
42. Hong, H.H., Houle, C.D., Ton, T.V., and Sills, R.C. (2007). K-ras mutations in lung tumors and tumors from other organs are consistent with a common mechanism of ethylene oxide tumorigenesis in the B6C3F1 mouse. Toxicol Pathol 35, 81-85.
43. Hong, H.H., Ton, T.V., Kim, Y., Wakamatsu, N., Clayton, N.P., Chan, P.C., Sills, R.C., and Lahousse, S.A. (2008). Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from B6C3F1 mice exposed to cumene. Toxicol Pathol 36, 720-726.
44. Horio, Y., Chen, A., Rice, P., Roth, J.A., Malkinson, A.M., and Schrump, D.S. (1996). Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog 17, 217-223.
45. Houle, C.D., Ton, T.V., Clayton, N., Huff, J., Hong, H.H., and Sills, R.C. (2006). Frequent p53 and H-ras mutations in benzene- and ethylene oxide-induced mammary gland carcinomas from B6C3F1 mice. Toxicol Pathol 34, 752-762.
46. Hsu, H.C., Tseng, H.J., Lai, P.L., Lee, P.H., and Peng, S.Y. (1993). Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness. Cancer Res 53, 4691-4694.
47. Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., and Miyake, M. (1998). Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 16, 2469-2477. (Pubitemid 28258579)
48. Huff, J.E., Melnick, R.L., Solleveld, H.A., Haseman, J.K., Powers, M., and Miller, R.A. (1985). Multiple organ carcinogenicity of 1,3-butadiene in B6C3F1 mice after 60 weeks of inhalation exposure. Science 227, 548-549.
49. Husain, K.D., Stromberg, P.E., Woolsey, C.A., Turnbull, I.R., Dunne, W.M., Javadi, P., Buchman, T.G., Karl, I.E., Hotchkiss, R.S., and Cooper-smith, C.M. (2005). Mechanisms of decreased intestinal epithelial proliferation and increased apoptosis in murine acute lung injury. Crit Care Med 33, 2350-2357.
50. Hutt, J.A., Vuillemenot, B.R., Barr, E.B., Grimes, M.J., Hahn, F.F., Hobbs, C.H., March, T.H., Gigliotti, A.P., Seilkop, S.K., Finch, G.L., Mauderly, J.L., and Belinsky, S.A. (2005). Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways. Carcinogenesis 26, 1999-2009.
51. Hwang, S.J., Cheng, L.S., Lozano, G., Amos, C.I., Gu, X., and Strong, L.C. (2003). Lung cancer risk in germline p53 mutation carriers: Association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113, 238-243.
52. Iarc. (1994). Ethylene oxide. IARC Monogr Eval Carcinog Risks Hum 60, 73-159.
53. Inga, A., Scott, G., Monti, P., Aprile, A., Abbondandolo, A., Burns, P.A., and Fronza, G. (1998). Ultraviolet-light induced p53 mutational spectrum in yeast is indistinguishable from p53 mutations in human skin cancer. Carcinogenesis 19, 741-746.
54. Ishak, K.G., and Glunz, P.R. (1967). Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer 20, 396-422.
55. Jackson, E.L., Olive, K.P., Tuveson, D.A., Bronson, R., Crowley, D., Brown, M., and Jacks, T. (2005). The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65, 10280-10288.
56. Jacoby, R.F., Llor, X., Teng, B.B., Davidson, N.O., and Brasitus, T.A. (1991). Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. J Clin Invest 87, 624-630.
57. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M.J. (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
58. Jeng, Y.M., Wu, M.Z., Mao, T.L., Chang, M.H., and Hsu, H.C. (2000). Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 152, 45-51.
59. Johnstone, C.N., Chang, L.M., and Ernst, M. (2002). AACR special meeting in cancer research: colon cancer-Genetics to prevention. Cancer Res 62, 6779-6783.
60. Kenemans, P., Verstraeten, R.A., and Verheijen, R.H. (2004). Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas 49, 34-43.
61. Kim, Y., Hong, H.H., Lachat, Y., Clayton, N.P., Devereux, T.R., Melnick, R.L., Hegi, M.E., and Sills, R.C. (2005). Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice. Toxicol Pathol 33, 307-312.
62. Kim, Y., Sills, R.C., and Houle, C.D. (2005). Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver. Toxicol Pathol 33, 175-180.
63. Kim, Y., Ton, T.V., DeAngelo, A.B., Morgan, K., Devereux, T.R., Anna, C., Collins, J.B., Paules, R.S., Crosby, L.M., and Sills, R.C. (2006). Major carcinogenic pathways identified by gene expression analysis of peritoneal mesotheliomas following chemical treatment in F344 rats. Toxicol Appl Pharmacol 214, 144-151.
64. Kinzler, K.W., and Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. Cell 87, 159-170.
65. Kiss, A., Wang, N.J., Xie, J.P., and Thorgeirsson, S.S. (1997). Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3, 1059-1066.
66. Kleihues, P., Louis, D.N., Scheithauer, B.W., Rorke, L.B., Reifenberger, G., Burger, P.C., and Cavenee, W.K. (2002). The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61, 215-225 ; discussion 226-229.
67. Koch, A., Denkhaus, D., Albrecht, S., Leuschner, I., von Schweinitz, D., and Pietsch, T. (1999). Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 59, 269-273.
68. Koujitani, T., Ton, T.V., Lahousse, S.A., Hong, H.H., Wakamatsu, N., and Sills, R.C. (2008). K-ras cancer gene mutations in lung tumors from female Swiss (CD-1) mice exposed transplacentally to 3′-azido-3′-deoxythymidine. Environ Mol Mutagen 49, 720-726.
69. Kumar, P., and Kratzke, R.A. (2005). Molecular prognostic markers in malignant mesothelioma. Lung Cancer 49 Suppl 1, S53-60.
70. Lahm, H., Gittner, K., Krebs, O., Sprague, L., Deml, E., Oesterle, D., Hoeflich, A., Wanke, R., and Wolf, E. (2002). Diethylnitrosamine induces long-lasting re-expression of insulin-like growth factor II during early stages of liver carcinogenesis in mice. Growth Horm IGF Res 12, 69-79.
71. Lambertini, L., Surin, K., Ton, T.V., Clayton, N., Dunnick, J.K., Kim, Y., Hong, H.H., Devereux, T.R., and Sills, R.C. (2005). Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy). Toxicol Pathol 33, 292-299.
72. Lerebours, F., and Lidereau, R. (2002). Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol 44, 121-141.
73. Lim, I.K. (2002). Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fischer 344 male rats. Mech Ageing Dev 123, 1665-1680.
74. Liu, Y.P., Lin, Y., and Ng, M.L. (1996). Immunochemical and genetic analysis of the p53 gene in liver preneoplastic nodules from aflatoxin-induced rats in one year. Ann Acad Med Singapore 25, 31-36.
75. Longato, L., de la Monte, S., Kuzushita, N., Horimoto, M., Rogers, A.B., Slagle, B.L., and Wands, J.R. (2009). Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 49, 1935-1943.
76. Lund, P., Schubert, D., Niketeghad, F., and Schirmacher, P. (2004). Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 206, 85-96.
77. Macaluso, M., Larson, R., Delzell, E., Sathiakumar, N., Hovinga, M., Julian, J., Muir, D., and Cole, P. (1996). Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry. Toxicology 113, 190-202.
78. Malkinson, A.M. (1992). Primary lung tumors in mice: An experimentally manipulable model of human adenocarcinoma. Cancer Res 52, 2670s - 76s.
79. Maltoni, C., and Scarnato, C. (1979). First experimental demonstration of the carcinogenic effects of benzene; long-term bioassays on Sprague-Dawley rats by oral administration. Med Lav 70, 352-357. (Pubitemid 10205287)
80. Mangues, R., and Pellicer, A. (1992). ras activation in experimental carcinogenesis. Semin Cancer Biol 3, 229-239.
81. Maronpot, R.R., Fox, T., Malarkey, D.E., and Goldsworthy, T.L. (1995). Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101, 125-156.
82. McCormick, F. (1999). Signalling networks that cause cancer. Trends Cell Biol 9, M53-56.
83. McCubrey, J.A., Steelman, L.S., Chappell, W.H., Abrams, S.L., Wong, E.W., Chang, F., Lehmann, B., Terrian, D.M., Milella, M., Tafuri, A., Stivala, F., Libra, M., Basecke, J., Evangelisti, C., Martelli, A.M., and Franklin, R.A. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773, 1263-1284.
84. McGuire, J.F., Ge, N.N., and Dyson, S. (2009). Nonmelanoma skin cancer of the head and neck I: Histopathology and clinical behavior. Am J Otolaryngol 30, 121-133.
85. Medina, D. (2008). Premalignant and malignant mammary lesions induced by MMTV and chemical carcinogens. J Mammary Gland Biol Neoplasia 13, 271-277.
86. Melnick, R.L., Sills, R.C., Portier, C.J., Roycroft, J.H., Chou, B.J., Grumbein, S.L., and Miller, R.A. (1999). Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice. Carcinogenesis 20, 867-878.
87. Meng, Q., Su, T., O′Neill, J.P., and Walker, V.E. (2002). Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3′-azido-3′-deoxythymidine and 2,′3′dideoxyinosinedagger. Environ Mol Mutagen 39, 282-295.
88. Meng, Q., Walker, D.M., Olivero, O.A., Shi, X., Antiochos, B.B., Poirier, M.C., and Walker, V.E. (2000). Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci U S A 97, 12667-12671.
89. Meuwissen, R., and Berns, A. (2005). Mouse models for human lung cancer. Genes Dev 19, 643-664.
90. Mirabelli-Primdahl, L., Gryfe, R., Kim, H., Millar, A., Luceri, C., Dale, D., Holowaty, E., Bapat, B., Gallinger, S., and Redston, M. (1999). Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59, 3346-3351.
91. Monti, P., Inga, A., Aprile, A., Campomenosi, P., Menichini, P., Ottaggio, L., Viaggi, S., Ghigliotti, G., Abbondandolo, A., and Fronza, G. (2000). p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVAtreated patients. Mutagenesis 15, 127-132.
92. Musti, M., Kettunen, E., Dragonieri, S., Lindholm, P., Cavone, D., Serio, G., and Knuutila, S. (2006). Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 170, 9-15.
93. Nataraj, A.J., Wolf, P., Cerroni, L., and Ananthaswamy, H.N. (1997). p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA). J Invest Dermatol 109, 238-243.
94. National Toxicology Program (NTP). (1987). Toxicology and Carcinogenesis Studies of Ethylene Oxide (CAS no. 75-21-8) in B6C3F1 Mice (Inhalation Studies). U.S. Department of Health and Human Services, National Institutes of Health, Research Triangle Park, NC.
95. National Toxicology Program (NTP). (1993). Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CAS no. 106-99-0) in B6C3F1 Mice (Inhalation Studies). Technical Report Series no. 434. NIH Publication no. 93-3165, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
96. National Toxicology Program (NTP). (1998). Toxicology and Carcinogenesis Studies of Chloroprene (CAS no. 126-99-8) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). Technical Report Series no. 467. NIH Publication no. 98-3957, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
97. National Toxicology Program (NTP). (2000). Ninth Report on Carcinogens. U.S. Department of Health and Human Services, Research Triangle Park, NC.
98. National Toxicology Program (NTP). (2002). Toxicology and carcinogenesis studies of 0-nitrotoluene sulfone (CAS no. 88-72-2) in F344/N rats and B6C3F(1) mice (feed studies). Natl Toxicol Program Tech Rep Ser, 1-357.
99. National Toxicology Program (NTP). (2004 a). Report on Carcinogens, 11 th ed. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, Research Triangle Park, NC.
100. National Toxicology Program (NTP). (2004 b). Toxicology and Carcinogenesis Studies of Transplacental AZT in Swiss (CD-1) Mice (In Utero Studies). NTP Technical Report 542.
101. National Toxicology Program (NTP). (2007). National Toxicology Program, toxicology and carcinogenicity studies of cumene in F344/N rats and B6C3F1 mice (inhalation studies). NTP Technical Report 542.
102. Nhieu, J.T., Renard, C.A., Wei, Y., Cherqui, D., Zafrani, E.S., and Buendia, M.A. (1999). Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155, 703-710.
103. Nikitin, A.Y., Alcaraz, A., Anver, M.R., Bronson, R.T., Cardiff, R.D., Dixon, D., Fraire, A.E., Gabrielson, E.W., Gunning, W.T., Haines, D.C., Kaufman, M.H., Linnoila, R.I., Maronpot, R.R., Rabson, A.S., Reddick, R.L., Rehm, S., Rozengurt, N., Schuller, H.M., Shmidt, E.N., Travis, W.D., Ward, J.M., and Jacks, T. (2004). Classification of proliferative pulmonary lesions of the mouse: Recommendations of the mouse models of human cancers consortium. Cancer Res 64, 2307-2316.
104. Norman, S.A., Berlin, J.A., Soper, K.A., Middendorf, B.F., and Stolley, P.D. (1995). Cancer incidence in a group of workers potentially exposed to ethylene oxide. Int J Epidemiol 24, 276-284.
105. Nygren, J., Cedervall, B., Eriksson, S., Dusinska, M., and Kolman, A. (1994). Induction of DNA strand breaks by ethylene oxide in human diploid fibroblasts. Environ Mol Mutagen 24, 161-167.
106. Olivero, O.A., Anderson, L.M., Diwan, B.A., Haines, D.C., Harbaugh, S.W., Moskal, T.J., Jones, A.B., Rice, J.M., Riggs, C.W., Logsdon, D., Yuspa, S.H., and Poirier, M.C. (1997). Transplacental effects of 3′azido-2, ′3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89, 1602-1608.
107. Olivero, O.A., Reddy, M.K., Pietras, S.M., and Poirier, M.C. (2001). Plasma drug levels compared with DNA incorporation of 3′-azido-3′- deoxythymidine (AZT) in adult cynomolgus (Macaca fascicularis) monkeys. Exp Biol Med (Maywood) 226, 446-449.
108. Olivero, O.A., Shearer, G.M., Chougnet, C.A., Kovacs, A.A., Landay, A.L., Baker, R., Stek, A.M., Khoury, M.M., Proia, L.A., Kessler, H.A., Sha, B.E., Tarone, R.E., and Poirier, M.C. (1999). Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. Aids 13, 919-925.
109. Peifer, M. (1997). Beta-catenin as oncogene: The smoking gun. Science 275, 1752-1753.
110. Phillips, M.D., Nascimbeni, B., Tice, R.R., and Shelby, M.D. (1991). Induction of micronuclei in mouse bone marrow cells: An evaluation of nucleoside analogues used in the treatment of AIDS. Environ Mol Mutagen 18, 168-183.
111. Pierceall, W.E., Goldberg, L.H., Tainsky, M.A., Mukhopadhyay, T., and Ananthaswamy, H.N. (1991). Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 4, 196-202.
112. Poirier, M.C., Divi, R.L., Al-Harthi, L., Olivero, O.A., Nguyen, V., Walker, B., Landay, A.L., Walker, V.E., Charurat, M., and Blattner, W.A. (2003). Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 33, 175-183.
113. Recio, L., Donner, M., Abernethy, D., Pluta, L., Steen, A.M., Wong, B.A., James, A., and Preston, R.J. (2004). In vivo mutagenicity and mutation spectrum in the bone marrow and testes of B6C3F1 lacI transgenic mice following inhalation exposure to ethylene oxide. Mutagenesis 19, 215-222.
114. Reynolds, S.H., Stowers, S.J., Patterson, R.M., Maronpot, R.R., and Anderson, M.W. (1988). Oncogene activation in spontaneous and chemically induced rodent tumors: Implications for risk analysis. Environ Health Perspect 78, 175-177.
115. Rosenberg, D.W., Giardina, C., and Tanaka, T. (2009). Mouse models for the study of colon carcinogenesis. Carcinogenesis 30, 183-196.
116. Russo, I.H., and Russo, J. (1996). Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104, 938-967.
117. Santamaria, A.B., Davis, D.W., Nghiem, D.X., McConkey, D.J., Ullrich, S.E., Kapoor, M., Lozano, G., and Ananthaswamy, H.N. (2002). p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death Differ 9, 549-560.
118. Santos-Burgoa, C., Matanoski, G.M., Zeger, S., and Schwartz, L. (1992). Lymphohematopoietic cancer in styrene-butadiene polymerization workers. Am J Epidemiol 136, 843-854.
119. Shore, R.E., Gardner, M.J., and Pannett, B. (1993). Ethylene oxide: An assessment of the epidemiological evidence on carcinogenicity. Br J Ind Med 50, 971-997.
120. Sills, R.C., Boorman, G.A., Neal, J.E., Hong, H.L., and Devereux, T.R. (1999). Mutations in ras genes in experimental tumours of rodents. In The Use of Short- and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation (D. B. McGregor, J. M. Rice, and S. Venitt, eds.). vol. 146, pp. 55-86. IARC Scientific Publications, Lyon, France.
121. Sills, R.C., Hong, H.L., Flake, G., Moomaw, C., Clayton, N., Boorman, G.A., Dunnick, J., and Devereux, T.R. (2004). o-nitrotoluene-induced large intestinal tumors in B6C3F1 mice model human colon cancer in their molecular pathogenesis. Carcinogenesis 25, 605-612.
122. Sills, R.C., Hong, H.L., Melnick, R.L., Boorman, G.A., and Devereux, T.R. (1999). High frequency of codon 61 K-ras A→T transversions in lung and Harderian gland neoplasms of B6C3F1 mice exposed to chloroprene (2-chloro-1,3-butadiene) for 2 years, and comparisons with the structurally related chemicals isoprene and 1,3-butadiene. Carcinogenesis 20, 657-662.
123. Snellings, W.M., Weil, C.S., and Maronpot, R.R. (1984). A two-year inhalation study of the carcinogenic potential of ethylene oxide in Fischer 344 rats. Toxicol Appl Pharmacol 75, 105-117.
124. Spivack, S.D., Fasco, M.J., Walker, V.E., and Kaminsky, L.S. (1997). The molecular epidemiology of lung cancer. Crit Rev Toxicol 27, 319-365.
125. Spugnini, E.P., Bosari, S., Citro, G., Lorenzon, I., Cognetti, F., and Baldi, A. (2006). Human malignant mesothelioma: Molecular mechanisms of pathogenesis and progression. Int J Biochem Cell Biol 38, 2000-2004.
126. Stayner, L., Steenland, K., Greife, A., Hornung, R., Hayes, R.B., Nowlin, S., Morawetz, J., Ringenburg, V., Elliot, L., and Halperin, W. (1993). Exposure-response analysis of cancer mortality in a cohort of workers exposed to ethylene oxide. Am J Epidemiol 138, 787-798.
127. Steenland, K., Stayner, L., Greife, A., Halperin, W., Hayes, R., Hornung, R., and Nowlin, S. (1991). Mortality among workers exposed to ethylene oxide. N Engl J Med 324, 1402-1407.
128. Steenman, M., Westerveld, A., and Mannens, M. (2000). Genetics of Beckwith-Wiedemann syndrome-associated tumors: Common genetic pathways. Genes Chromosomes Cancer 28, 1-13.
129. Suzuki, Y., and Yuen, S.R. (2002). Asbestos fibers contributing to the induction of human malignant mesothelioma. Ann N Y Acad Sci 982, 160-176.
130. Takahashi, T., Nau, M.M., Chiba, I., Birrer, M.J., Rosenberg, R.K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A.F., and Minna, J.D. (1989). p53: A frequent target for genetic abnormalities in lung cancer. Science 246, 491-494.
131. Takayasu, H., Horie, H., Hiyama, E., Matsunaga, T., Hayashi, Y., Watanabe, Y., Suita, S., Kaneko, M., Sasaki, F., Hashizume, K., Ozaki, T., Furuuchi, K., Tada, M., Ohnuma, N., and Nakagawara, A. (2001). Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res 7, 901-908.
132. Tan, D.S., Marchio, C., and Reis-Filho, J.S. (2008). Hereditary breast cancer: From molecular pathology to tailored therapies. J Clin Pathol 61, 1073-1082.
133. Teta, M.J., Benson, L.O., and Vitale, J.N. (1993). Mortality study of ethylene oxide workers in chemical manufacturing: A 10 year update. Br J Ind Med 50, 704-709.
134. Thorgeirsson, S.S., and Grisham, J.W. (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31, 339-346.
135. Ton, T.V., Hong, H.H., Devereux, T.R., Melnick, R.L., Sills, R.C., and Kim, Y. (2007). Evaluation of genetic alterations in cancer-related genes in lung and brain tumors from B6C3F1 mice exposed to 1,3-butadiene or chloroprene. Chem Biol Interact 166, 112-120.
136. Turusov, V.S., Torii, M., Sills, R.C., Willson, G.A., Herbert, R.A., Hailey, J.R., Haseman, J.K., and Boorman, G.A. (2002). Hepatoblastomas in mice in the US National Toxicology Program (NTP) studies. Toxicol Pathol 30, 580-591.
137. Tward, A.D., Jones, K.D., Yant, S., Cheung, S.T., Fan, S.T., Chen, X., Kay, M.A., Wang, R., and Bishop, J.M. (2007). Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A 104, 14771-14776.
138. Vivet-Boudou, V., Didierjean, J., Isel, C., and Marquet, R. (2006). Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell Mol Life Sci 63, 163-186.
139. von Schweinitz, D., Leuschner, I., Gluer, S., and Pietsch, T. (1996). Expression of cell adhesion molecules and common acute lymphoblastic leukaemia antigen in hepatoblastoma. Virchows Arch 429, 235-241.
140. Von Tungeln, L.S., Hamilton, L.P., Dobrovolsky, V.N., Bishop, M.E., Shaddock, J.G., Heflich, R.H., and Beland, F.A. (2002). Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F(1)/Tk+/- mice treated neonatally with zidovudine and lamivudine. Carcinogenesis 23, 1427-1432.
141. Wade, T.R., and Ackerman, A.B. (1978). The many faces of squamous-cell carcinomas. J Dermatol Surg Oncol 4, 291-294.
142. Wakamatsu, N., Collins, J.B., Parker, J.S., Tessema, M., Clayton, N.P., Ton, T.V., Hong, H.H., Belinsky, S., Devereux, T.R., Sills, R.C., and Lahousse, S.A. (2008). Gene expression studies demonstrate that the K-ras/Erk MAP kinase signal transduction pathway and other novel pathways contribute to the pathogenesis of cumene-induced lung tumors. Toxicol Pathol 36, 743-752.
143. Wakamatsu, N., Devereux, T.R., Hong, H.H., and Sills, R.C. (2007). Overview of the molecular carcinogenesis of mouse lung tumor models of human lung cancer. Toxicol Pathol 35, 75-80.
144. Wang, Y., Zhang, Z., Lubet, R.A., and You, M. (2006). A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. Oncogene 25, 1277-1280.
145. Watanabe, K., Tachibana, O., Sata, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1996). Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6, 217-223 ; discussion 23-24.
146. Westra, W.H., Offerhaus, G.J., Goodman, S.N., Slebos, R.J., Polak, M., Baas, I.O., Rodenhuis, S., and Hruban, R.H. (1993). Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 17, 213-220.
147. Westra, W.H., Slebos, R.J., Offerhaus, G.J., Goodman, S.N., Evers, S.G., Kensler, T.W., Askin, F.B., Rodenhuis, S., and Hruban, R.H. (1993). K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72, 432-438.
148. Whitson, B.A., and Kratzke, R.A. (2006). Molecular pathways in malignant pleural mesothelioma. Cancer Lett 239, 183-189.
149. Wong, C.M., Lee, J.M., Ching, Y.P., Jin, D.Y., and Ng, I.O. (2003). Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 63, 7646-7651.
150. Yamada, Y., and Mori, H. (2007). Multistep carcinogenesis of the colon in Apc(Min/+) mouse. Cancer Sci 98, 6-10.
151. Yamada, Y., Yoshimi, N., Sugie, S., Suzui, M., Matsunaga, K., Kawabata, K., Hara, A., and Mori, H. (1999). Beta-catenin (Ctnnb1) gene mutations in diethylnitrosamine (DEN)-induced liver tumors in male F344 rats. Jpn J Cancer Res 90, 824-828.
152. Yamamoto, Y., Sakamoto, M., Fujii, G., Tsuiji, H., Kenetaka, K., Asaka, M., and Hirohashi, S. (2003). Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 37, 528-533.
153. Zhang, Z., Wang, Y., Vikis, H.G., Johnson, L., Liu, G., Li, J., Anderson, M.W., Sills, R.C., Hong, H.L., Devereux, T.R., Jacks, T., Guan, K.L., and You, M. (2001). Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29, 25-33.